NASDAQ:AGTC - Applied Genetic Technologies Stock Price, Price Target & More

Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."

Applied Genetic Technologies Corp (NASDAQ:AGTC) issued its quarterly earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by $0.04. The biotechnology company had revenue of $3.60 million for the quarter, compared to analyst estimates of $6.41 million. Applied Genetic Technologies had a negative return on equity of 16.00% and a negative net margin of 65.96%. View Applied Genetic Technologies' Earnings History.

Applied Genetic Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, September, 12th 2018. View Earnings Estimates for Applied Genetic Technologies.

5 brokers have issued 1 year price targets for Applied Genetic Technologies' stock. Their forecasts range from $7.00 to $12.00. On average, they expect Applied Genetic Technologies' stock price to reach $9.00 in the next year. This suggests a possible upside of 116.9% from the stock's current price. View Analyst Ratings for Applied Genetic Technologies.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Applied Genetic Technologies include MeiraGTx (MGTX), Jounce Therapeutics (JNCE), Nantkwest (NK), Allena Pharmaceuticals (ALNA), Agenus (AGEN), ADMA Biologics (ADMA), Idera Pharmaceuticals (IDRA), Krystal Biotech (KRYS), Fennec Pharmaceuticals (FENC), Compugen (CGEN), Organovo (ONVO), Pluristem Therapeutics (PSTI), Cidara Therapeutics (CDTX), Eiger Biopharmaceuticals (EIGR) and Aptose Biosciences (APTO).

Media coverage about AGTC stock has trended somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Applied Genetic Technologies earned a media sentiment score of 0.24 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 47.11 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Applied Genetic Technologies' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Municipal Employees Retirement System of Michigan (1.33%). Company insiders that own Applied Genetic Technologies stock include Ivana Magovcevic, Jeffrey D Chulay, Lawrence E Bullock, Mark S Shearman and Stephen W Potter. View Institutional Ownership Trends for Applied Genetic Technologies.

AGTC stock was sold by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan. View Insider Buying and Selling for Applied Genetic Technologies.

Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of AGTC stock can currently be purchased for approximately $4.15.

Applied Genetic Technologies has a market capitalization of $76.06 million and generates $39.47 million in revenue each year. The biotechnology company earns $400,000.00 in net income (profit) each year or $0.02 on an earnings per share basis. Applied Genetic Technologies employs 72 workers across the globe.

Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at 386-462-2204.